Changes in biological source material

Area of Science:

• Biotechnology
• Pharmaceutical Science
• Regulatory Affairs

Background:

• Biologics manufacturing involves sourcing raw materials, which can change over a product's lifecycle.
• Changes can range from radical (e.g., plasma-derived to recombinant DNA) to subtle (e.g., serum inactivation).
• Such modifications necessitate careful evaluation due to potential impacts on product quality and safety.

Purpose of the Study:

• To analyze the regulatory and scientific implications of changes in raw materials for biotech medicinal products.
• To highlight the importance of comparability studies following subtle manufacturing changes.
• To emphasize a case-by-case assessment of product alterations.

Main Methods:

• Review of regulatory consequences for different types of raw material changes.
• Discussion of comparability studies to assess product alterations due to subtle changes.
• Case-by-case evaluation framework for product efficacy and immunogenicity.

Main Results:

• Radical source material changes (e.g., plasma to recombinant DNA) have major regulatory consequences.
• Subtle changes (e.g., serum inactivation) primarily driven by viral safety needs have less severe regulatory implications.
• Subtle changes can induce inadvertent alterations in product attributes via cell metabolism, requiring comparability assessments.

Conclusions:

• Manufacturing strategy drives radical changes, while viral safety concerns often drive subtle changes.
• Comparability studies are crucial for subtle changes to address potential alterations in cell metabolism and product attributes.
• The impact of any change on a biotech product's efficacy and immunogenicity must be assessed individually.